TEST CHANGE

Myasthenia Gravis Reflexive Panel

3001869, MG R PAN

Specimen Requirements:	
Patient Preparation:	
Collect:	Serum Separator Tube (SST).
Specimen Preparation:	Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Transport Temperature:	Refrigerated.
Unacceptable Conditions:	Contaminated, hemolyzed, or severely lipemic specimens.
Remarks:	
Stability:	After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month (avoid repeated freeze/thaw cycles)
Methodology:	Quantitative Radioimmunoassay (RIA)/~~/~~Semi-Quantitative Flow Cytometry
Performed:	Sun-Sat
Reported:	3-8 days
Note:	If Acetylcholine Receptor Binding Antibody result is greater than 0.4 nmol/L or Acetylcholine Receptor Blocking Antibody result is greater than 26 percent, then Acetylcholine Receptor Modulating Antibody (ARUP test code 0099521) will be added. If Acetylcholine Receptor Binding Antibody result is less than or equal to 0.4 nmol/L, then Muscle-Specific Kinase (MuSK) Ab, IgG (ARUP test code 300619857~~6~~) will be added. Additional charges apply.
CPT Codes:	83519; 83516; if reflexed, add 83516 or 86255; if reflexed add 86256~~, 83519~~
New York DOH Approval Status:	This test is New York DOH approved.
Interpretive Data:	

Approximately 85-90 percent of patients with myasthenia gravis (MG) express antibodies to the acetylcholine receptor (AChR), which can be divided into binding, blocking, and modulating antibodies. Binding antibody can activate complement and lead to loss of AChR. Blocking antibody may impair binding of acetylcholine to the receptor, leading to poor muscle contraction. Modulating antibody causes receptor endocytosis resulting in loss of AChR expression, which correlates most closely with clinical severity of disease. Approximately 10-15 percent of individuals with confirmed myasthenia gravis have no measurable binding, blocking, or modulating antibodies.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Components	Interpretive Data
Acetylcholine Binding Antibody	0.0-0.4 nmol/L: Negative 0.5 nmol/L or greater: Positive
Acetylcholine Blocking Antibody	0-26% blocking: Negative 27-41% blocking: Indeterminate 42% or greater blocking: Positive

Reference Interval:

Test Number	Components	Reference Interval
	Acetylcholine Binding Antibody	0.4 nmol/L or less
	Acetylcholine Blocking Antibody	26 % blocking or less

HOTLINE NOTE: There is a reflexive pattern change associated with this test. One or more orderable or component has been added or removed to the reflexive pattern. Refer to the Hotline Test Mix for interface build information.